Deborah Stapel
Nurse Practitioner · Fort Worth, TXNPI 1316910706
Payments from drug & device makers
Across 1,151 payments — averaging $38.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$27K
- Biogen$1K
- UCB, Inc.$957
- Acadia Pharmaceuticals Inc$801
- Grifols USA, LLC$685
- EMD Serono, Inc.$684
- plus $12K from 54 others
What the payments were for
- Consulting fees$4501%
- Speaking & faculty fees$23,35553%
- Food & beverage$19,84845%
- Education$2150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,867 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 30 | $156,970 |
| RytaryCarbidopa/Levodopa | 67 | $106,040 |
| Aimovig AutoinjectorErenumab-Aooe | 48 | $35,020 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 30 | $30,599 |
| Emgality PenGalcanezumab-Gnlm | 36 | $25,355 |
| Memantine Hcl | 297 | $9,561 |
| Emgality SyringeGalcanezumab-Gnlm | 13 | $9,404 |
| Gabapentin | 403 | $7,842 |
| Primidone | 189 | $7,701 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 177 | $5,578 |
| Duloxetine Hcl | 154 | $4,506 |
| Carbamazepine ErCarbamazepine | 43 | $4,413 |
| Quetiapine Fumarate | 175 | $4,297 |
| RivastigmineRivastigmine Tartrate | 78 | $4,292 |
| Zolmitriptan | 18 | $4,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $801 | $156,97030 claims |
| Amneal Pharmaceuticals LLCRytary | $403 | $106,04067 claims |
| Upsher-smith Laboratories LLCTopiramate | $378 | $1,33498 claims |
| Almatica Pharma LLCSertraline Hcl | $54 | $57656 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Fort Worth
- Jessica RothFort Worth$15K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Kelly BrassilHouston$194K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Monica WhiteLongview$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.